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original work is propObjective: To determine the uptake of home-based HIV counselling and testing (HCT)
in four HPTN 071 (PopART) trial communities (implementing a ‘full’ combination HIV
prevention package that includes universal HIV testing and treatment) in Zambia. We
also explore factors associated with uptake of HCT in these communities.
Design: HPTN 071 (PopART) is a three-arm community-randomized trial in 12 com-
munities in Zambia and nine communities in South Africa evaluating the impact of a
combination HIV prevention package, including universal HIV testing and treatment,
on HIV incidence.
Methods: Using a door-to-door approach that includes systematically revisiting house-
holds, individuals were offered participation in the intervention, and verbal consent was
obtained. Data were analysed for the first 18 months of the intervention, December
2013 to June 2015 for individuals 18 years and older.
Results: Among 121 130 enumerated household members, 101 102 (83.5%) accepted
the intervention. HCT uptake was 72.2% (66 894/92 612), similar by sex but varied
across communities. HCT uptake was associated with younger age, sex, community,
being symptomatic for TB and sexually transmitted infections and longer time since
previous HIV test. Knowledge of HIV status due to the intervention increased by 36%
overall and by 66% among HIV positive participants; the highest impact was among
18–24 years old.
Conclusion: Overall acceptance of HIV-testing through offering a door-to-door-based
combination HIV prevention package was 72.2%. The intervention increased knowl-
edge of HIV status from 50 to 90%. However, challenges still remain and a one-off
intervention is unlikely to be successful but will require repeated visits and multiple
strategies. Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2017, 31:1555–1564Keywords: community, HIV, home-based HIV counselling and testing, universal
HIV testing and immediate treatment, ZambiaIntroduction
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globally [1]. In Zambia, HIV prevalence in the
population aged 15–49 years is estimated to be 13.3% [2].
Voluntary HIV counselling and testing (HCT) has been
shown to result in knowledge of one’s HIV status and
reduction in sexual risk behaviour in certain populations
[3,4]. Knowing one’s HIV status is the first step in
accessing prevention and treatment services. HIV-positive
individuals who do not know their status might
unknowingly contribute towards onward HIV trans-
mission and have a higher personal risk of developing
opportunistic infections which could lead to early death
[5].
Uptake of HIV testing has shown remarkable increases in
the past 6 years (2009–2015) in Zambia. In the 2013–
2014 Demographic Health Survey (DHS), the pro-
portions of participants aged 15–49 years who have ever
been tested for HIV was 80% in women compared with
64% in men [2]. However, the proportions of those tested
in the previous 12 months remained quite low (women –
46%, men – 37%) [2]. Similarly, many countries in SSA
show low levels of HCT uptake. According to a report
using nationally representative data on HIV-testing,
uptake from 47 surveys in 29 SSA countries that
conducted DHS between 2003 and 2011, the percentage
of participants aged 15–49 years whowere ever tested for
HIVand received results of the most recent test was 28.8%
for women and 17.2% for men [6].
Modelling reports suggest that a ‘universal test-and-
treat’ (UTT) [7] approach can provide significant HIV
prevention benefits but only when very high levels of
uptake of universal HIV testing and immediate
treatment are achieved and sustained [8,9]. However,
challenges of attaining high levels of UTT under
routine settings have been widely acknowledged. Four
large-scale cluster randomized trials in SSA to measure
the feasibility and efficacy of a UTT approach in ‘real
life’ [10–13] have provided the much needed evidence.
One of these, the HPTN 071 trial, also known as
PopART (Population Effects of Antiretroviral Therapy
to reduce HIV Transmission) trial is a three-arm
community randomized trial in 12 communities in
Zambia and nine communities in South Africa
evaluating the impact of a combination HIV prevention
package, including UTT, on community-level HIV
incidence over a 5-year period [12]. This trial is
currently ongoing.
We report on the uptake of HCT in four HPTN 071
(PopART) trial communities (implementing a ‘full’
combination HIV prevention package that includes
UTT through a door-to-door approach) in Zambia after
the first 18 months (first round) of the intervention. We
also explore factors associated with uptake of HCT in
these communities. Copyright © 2017 Wolters Kluwer HMethods
Trial design
Full details of the HPTN 071 (PopART) design have
been described elsewhere [12]. In brief, the 21 study
communities were formed into seven matched triplets
(four triplets in Zambia and three triplets in South Africa)
and randomly allocated to three study arms. Arm A is
receiving the full PopART intervention including
immediate antiretroviral therapy (ART) irrespective of
CD4þ cell count. The adult (18 years old) population of
the four Arm A communities in Zambia and the three
Arm A communities in South Africa is estimated to be
approximately 104 000 and 55 000, respectively. The
study is being carried out in areas known to have high
HIV prevalence (approximately 15–20%) and is con-
tinuing to experience severe generalized HIV epidemics
[12].
We report on the adult population aged 18 years and
above from the four Arm A communities in Zambia only.
The PopART intervention
The PopART combination HIV prevention package is
delivered by a cadre of community workers called
Community HIV Care Providers (CHiPs). All household
members living in the intervention areas are offered the
PopART intervention. The intervention includes
‘annual’ rounds of home-based HCT (HB-HCT) with
linkage to prevention and care. Individuals found to be
HIV-positive are referred to the local government clinics
for linkage to HIV care and ART irrespective of CD4þ
cell count with ongoing support for adherence and
retention in care. Individuals receive information on HIV
prevention and are offered condoms and screened for
symptoms of tuberculosis (TB) and sexually transmitted
infections (STIs). Symptomatic individuals for TB and
STI are referred to the clinic for further management.
Uncircumcised HIV-negative men are referred for
voluntary medical circumcision (VMMC) at the clinic.
CHiPs are lay counsellors who work in pairs; each pair is
allocated a zone of the community. A total of 103 CHiPs
pairs work in the four intervention communities. The
CHiP pair enumerate all household members and
systematically visit all households in their zones to offer
testing and retesting using HIV rapid tests. The teams
return to households in their zones throughout the year as
necessary to follow-up on referrals and linkages to care and
offer testing to absent household members or those who
previously declined testing. CHiPs record household
activities on an electronic data capture (EDC) device.
Consent to participate and to start ART
regardless of CD4R cell count
All household members are asked for verbal informed
consent to take part in the intervention and permission to
collect data on the EDC device. Consent to participateealth, Inc. All rights reserved.
Reaching universal HIV testing Shanaube et al. 1557does not necessarily include consent for an HIV test,
although this is encouraged. Information is given about
the risks and benefits of UTT and participants give
written informed consent to start ART outside national
guidelines at the clinic.
Home-based HIV counselling and testing
HCT is offered to all household members. Written
consent for HCT is obtained from adults. Household
members who agree to HCT have the option to receive it
as couples, a household group, or individually. HIV
testing is carried out using Alere Determine HIV-1/2 test
(Alere International Limited, Matsudo-shi, Chiba, Japan)
as a screening test and the Unigold HIV test (Trinity
Biotech Manufacturing Ltd, Bray, Co. Wicklow, Ireland)
as the confirmative test for individuals who have a reactive
result on the screening test.
Data collection
The household activities of CHiPs are electronically
logged using a password-protected EDC device. Data
collected include socio-demographic and clinical data
which are synchronized daily to a central server. The
EDC programme encrypts the names, addresses, and
global positioning system-coordinates of the visited
households to minimize the risk of identification of
participants by individuals other than CHiPs.
Statistical analysis
Data were collected from December 2013 to June 2015
and analysed using Stata V.13. Coverage of the
intervention and possible biases in the inclusion of
participants was explored by studying households
consenting, age and sex distribution of those enumerated
as a household member, age and sex distribution of those
consenting to the intervention, and the proportion
refusing or not contacted by CHiPs.
Analysis was restricted to participants aged 18 years and
older, eligible for HIV-testing that is, all adults who did
not self-report to be HIV-positive. Explanatory variables
were limited to those variables collected by CHiPs and
included community, age, sex, date previously tested for
HIV, number of adults in the household, TB symptoms,
STI symptoms, whether circumcised (men) or pregnant
(women).
Univariable and multivariable random-effects logistic
regression was used to estimate unadjusted and adjusted
odds ratios (aOR), with all analysis controlled for
community. Analysis was done separately for men and
women, with zone as a random effect to account for
clustering due to variation in CHiPs’ performance. The
likelihood ratio test was used to compare the fit of
different models and quantify evidence of associations
between individual characteristics and HCT uptake. In
multivariable models, age group and prior history of
HIV-testing were considered for inclusion first, and Copyright © 2017 Wolters Kluweconfounding among community, age group, and previous
history of HIV-testing was explored. Following this,
other explanatory variables were considered and those
that had weak evidence of association with the outcome
(P< 0.10) were included, with robust standard errors to
account for clustering by zone. Analysis was restricted to
individuals with complete data.
Variables recorded by CHIPs on the EDC were selected
primarily to support and monitor provision of the service
by the CHiPs.Knowledge of HIV status before the intervention
was defined as self-reported HIV-positive or tested HIV-
negative elsewhere in the previous 12 months. Knowledge
of HIV status after intervention was defined as self-reported
HIV-positive and tested by CHiPs or tested HIV-negative
elsewhere in the previous 12 months.
HIV-prevalence among participants was calculated using
the formula: (self-reported HIV-positive partici-
pants)þ (tested by CHiPs)þ (estimated HIV-positive
among those accepting the intervention but decline
HIV-testing)/(all participants).
The estimated HIV-positive among those accepting the
intervention but decline HIV-testing was calculated using
predictions obtained from a multivariable logistic
regression model whose outcome was HIV status, and
including in the analysis all adults who did not self-report
they were HIV-positive and accepted the offer of testing
from CHiPs.
Ethical approval
Ethics approval was obtained from the ethics committees
of the University of Zambia (UNZA BREC) and the
London School of Hygiene and Tropical Medicine.
Permission to conduct the study was received from the
Ministry of Health.Results
Participation
From December 2013 to June 2015, 48 583 households
were visited. More households were visited than had
been counted during household census in 2013 (46 762)
due to new houses being built and additional households
moving in (Fig. 1). Most households consented to the
intervention (47 006/48 583; 96.8%). Enumeration of
individual household members was completed for 99.4%
(46 714/47 006) of the consenting households. Average
household size was 4.6 (214 369 members in 46 714
households). Women were less likely to refuse to the
intervention than men [5.0% versus 8.2%, aOR 0.55,
95% confidence interval (CI): 0.53–0.58]. CHiPs were
not able to contact 14.2% of men and 4.0% women
(Fig. 1).r Health, Inc. All rights reserved.
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46,762 HH in  
household census
48,583 HH approached   
(103.9%)
214,369  HH members 
enumerated
121,130  ≥18 years  
enumerated (56.5%)
1,577 (3.2%) HH refused/no one present
47,006 HH consent 
(96.8%)
292 (0.6%) HH not enumerated 
46,714 HH 
enumerated (99.4%)
93,239 (43.5%) < 18 years of age
59,283 adult men   
MEN WOMEN
(48.9%) 4,871 refused parcipaon (8.2%)
618 pending (1.0%)
8,395 not contacted (14.2%)  
380 health data not recorded (0.8%)
45,399 consented to 
intervenon (76.6%)
45,019 health data 
recorded (99.2%)
2,423 self-reported 
HIV+ (5.4%)
42,596 eligible for HIV-
tesng (94.6%)
30,226 accepted HIV-
tesng (71.0%)
12,370 declined HIV-
tesng (29.0%)
61,847 adult  women   
(51.1%) 3,101 refused parcipaon (5.0%)
577 pending (0.9%)
2,466 not contacted (4.0%)  
378 health data not recorded (0.7%)
55,703 consented to 
intervenon (90.1%)
55,325 health data 
recorded (99.3%)
5,309 self-reported 
HIV+ (9.6%)
50,016 eligible for HIV-
tesng (90.4%)
36,668 accepted HIV-
tesng (73.3%)
13,348 declined HIV-
tesng (26.7%)
Fig. 1. Flow chart showing PopART intervention participation and HIV-testing eligibility. HH, Households.A total of 101 102 (83.5%; 101 102/121 130) household
members consented (accepted) the intervention of
whom 44.9% (45 399/101 102) were men, and 55.1%
(55 703/101 102) were women. For 100 344 partici-
pants out of 101 102 (99.3%), health data were
electronically recorded after accepting the intervention.
In total, 7732 (7.7%; 7732/100 344) participants self-
reported to be HIV-positive; 2423 men and 5309
women, leaving 92 612 participants eligible for HIV-
testing (46% men, 54% women). Overall, 72.2%
(66 894/92 612) participants accepted HIV-testing by
the CHiPs. HCT uptake was similar by sex (73.3%
women; 71% men).
Factors associated with uptake of HIV
counselling and testing
ORs were generally similar in univariable and multi-
variable analyses, showing little confounding. In multi-
variable analysis, factors strongly associated with HCT
uptake were community, younger age, longer time since
previous HIV test, and being symptomatic for TB or STI
(Table 1).
Comparedwith community 3, participants in community
2 were more likely to accept HCT (aOR 1.54; 95% CI:
1.03–2.27 in men, 1.69, 95% CI 1.19–2.44 in women),
whereas those in community 1 were more likely to
decline, particularly men (aOR 0.26, 95% CI: 0.16–0.44
in men, 0.39, 95% CI 0.25–0.63 in women). Copyright © 2017 Wolters Kluwer HParticipants aged 18–19 years had the highest HCT
uptake with a trend towards increasing refusal from ages
20 to 50. Participants aged 50 years and older were more
likely to decline HCT (aOR 0.34, 95% CI 0.30–0.34 in
men; 0.31, 95% CI 0.28–0.34 in women).
Participants recently tested for HIV had the lowest HCT
uptake compared with those who never tested (aOR:
0.13, 95%CI 0.12–0.14 in men; 0.17, 95%CI 0.16–0.19
in women). Men living in households with one other
adult member had lower HCTuptake (aOR 0.61, 95%CI
0.54–0.69) compared with a single adult man, whereas
for women, difference in HCT uptake according to
household size was small.
Being symptomatic for TB was the most noteworthy
factor associated with higher HCT uptake, although a
low percentage of the population reported TB
symptoms. Compared with asymptomatic participants,
those symptomatic for TB were more likely to accept
HCT (aOR: 4.55, 95% CI 3.33–6.25 in men, 3.03,
95% CI 2.22–4.00 in women). A similar trend was
seen for participants reporting STI symptoms (aOR:
3.33, 95% CI 2.50–4.35 in men; 3.45, 95% CI 2.70–
4.55 in women). Evidence of an association between
VMMC and HCT uptake was less convincing. Being
pregnant was associated with lower HCT uptake in
univariable analysis (OR 0.71, 95% CI 0.65–0.76), but
there was no evidence of an association in multivariable
analysis.ealth, Inc. All rights reserved.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Table 2. Self-reported HIV-positive and newly HIV-positive identified by Community HIV care Providers in men.
Characteristic
Total
consented to
intervention
Self-
reported
HIVþ
Tested
HIVþ
% Tested
HIVþ
Known
HIVþ after
intervention
Known
HIVþ among
consented after
intervention (%)
Proportion
HIVþ diagnosed
by the
CHiPs (%)
HIV-
prevalence
among
consenters (%)
Total 45 019 2423 1715 5.7 4138 9.2 41.4 10.3
Community
1 5640 176 74 2.6 250 4.4 29.6 5.6
2 9871 552 556 7.2 1108 11.2 50.2 12.2
3 22 635 1215 865 5.5 2080 9.2 41.6 10.2
4 6873 480 220 5.7 700 10.2 31.4 11.9
Age
18–19 4461 17 14 0.4 31 0.7 45.2 0.7
20–24 9182 47 130 1.8 177 1.9 73.4 2.2
25–29 7848 161 330 6.0 491 6.3 67.2 7.3
30–39 12 540 941 764 9.9 1705 13.6 44.8 15.5
40–49 6109 852 335 9.8 1187 19.4 28.2 21.3
50 4879 405 142 5.0 547 11.2 26.0 12.3
Previous HIV test
Not tested 14 989 0 818 6.6 818 5.5 100.0 6.5
0–3 months 6167 197 64 3.0 261 4.2 24.5 5.9
4–6 months 4844 178 117 3.9 295 6.1 39.7 7.2
7–9 months 3232 138 76 3.5 214 6.6 35.5 7.5
10–12 months 2498 135 86 5.0 221 8.8 38.9 10.0
12 months 12 104 1681 509 6.3 2190 18.1 23.2 19.1
Unknown 859 94 36 6.1 130 15.1 27.7 16.3
Missing 326 0 9 7.8 9 2.8 100.0
Household size
1 adult 2165 136 136 8.6 272 12.6 50.0 13.9
2 adults 16 980 1253 760 7.4 2013 11.9 37.8 13.5
3 adults 9117 458 308 5.0 766 8.4 40.2 9.4
>3 adults 16 757 576 511 4.2 1087 6.5 47.0 7.2
TB
Not presumptive TB 44 049 2206 1526 5.2 3732 8.5 40.9 9.6
On treatment 224 111 21 27.6 132 58.9 15.9 62.1
Presumptive TB case 746 106 168 29.0 274 36.7 61.3 38.3
STI
Not symptomatic 44 170 2344 1586 5.4 3930 8.9 40.4 10.0
Symptomatic 763 77 127 20.9 204 26.7 62.3 28.4
Missing 86 2 2 3.1 4 4.7 50.0
Circumcision
Not circumcised 24 772 1832 1382 8.1 3214 13.0 43.0 14.6
VMMC 13 829 303 172 1.9 475 3.4 36.2 3.8
Traditional 5411 221 132 3.8 353 6.5 37.4 7.7
Missing 1007 67 29 5.7 96 9.5 30.2
CHiPs, Community HIV care Providers; HIVþ, HIV-positive; STI, sexually transmitted infections; TB, tuberculosis.Effect modification
Although there was evidence of effect modification
between community, age, and previous HIV testing
history, it was the strength of association that varied rather
than the direction of association. For this reason, overall
findings only are presented. As including interaction
terms did not change the overall message, stratified ORs
are not shown.
Proportion of HIV-positive participants among
those who consented
Self-reported HIV-positive participants
Overall, 5.4% (2423/45 019) of men and 9.6% (5309/
55 325) of women self-reported to be HIV-positive,
varying by community and age (Tables 2 and 3). The
proportion of participants reporting to be HIV-positive
increased with age for those aged 18–49. Most self- Copyright © 2017 Wolters Kluwer Hreported HIV-positive participants were diagnosed more
than 12 months previously (13.9% men and 22.1%
women). Expectedly, the highest proportion of self-
reported HIV-positive status was seen in participants on
TB-treatment (49.6% men and 57.1% women).
Newly diagnosed HIV-positive participants
Among those who accepted the offer of HCT, 5.7%
(1715/30 226) of men and 9.3% (3393/36 668) of women
were newly diagnosed by CHiPs as being HIV-positive.
The proportion of participants diagnosed as newly HIV-
positive was lowest in the 18–19 age group (0.4% men;
3.5% women) (Tables 2 and 3). For both men and
women, the highest proportion of newly diagnosed with
HIV was found among those symptomatic for TB (29.0%
in men and 40.6% in women) and STI (20.9% in men andealth, Inc. All rights reserved.
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Table 3. Self-reported HIV-positive and newly HIV-positive identified by Community HIV care Providers in women.
Characteristic
Total
consented to
intervention
Self-reported
HIVþ
Accept
test
Tested
HIVþ
% Tested
HIVþ
Known
HIVþ after
intervention
Known HIVþ
among consented
after intervention (%)
Proportion HIVþ
diagnosed by
the CHiPs (%)
HIV-prevalence
among
consenters (%)
Total 55 325 5309 36 668 3393 9.3 8702 15.7 39.0 17.5
Community
1 6769 382 3994 236 5.9 618 9.1 38.2 11.0
2 13 077 1140 9907 982 9.9 2122 16.2 46.3 17.5
3 26 074 2508 17 690 1617 9.1 4125 15.8 39.2 17.3
4 9405 1279 5077 558 11.0 1837 19.5 30.4 22.5
Age
18–19 6675 80 5474 191 3.5 271 4.1 70.5 4.5
20–24 13 764 491 10 218 822 8.0 1313 9.5 62.6 10.8
25–29 10 149 898 6599 778 11.8 1676 16.5 46.4 18.8
30–39 13 307 2297 7720 1029 13.3 3326 25.0 30.9 27.4
40–49 5627 1070 3174 378 11.9 1448 25.7 26.1 27.9
50 5803 473 3483 195 5.6 668 11.5 29.2 12.9
Previous HIV test
Not tested 10 810 0 8877 900 10.1 900 8.3 100.0 10.1
0–3 months 9846 441 4186 213 5.1 654 6.6 32.6 9.3
4–6 months 7647 363 5294 323 6.1 686 9.0 47.1 10.5
7–9 months 5030 328 3749 300 8.0 628 12.5 47.8 13.9
10–12 months 3811 323 2845 261 9.2 584 15.3 44.7 16.8
12 months 16 784 3710 10 849 1314 12.1 5024 29.9 26.2 31.4
Unknown 1145 143 779 65 8.3 208 18.2 31.3 19.6
Missing 252 1 89 17 19.1 18 7.1 94.4
Household size
1 adult 3235 610 1893 328 17.3 938 29.0 35.0 32.0
2 adults 22 545 2445 14 225 1452 10.2 3897 17.3 37.3 19.3
3 adults 11 337 1033 7637 651 8.5 1684 14.9 38.7 16.4
>3 adults 18 208 1221 12 913 962 7.4 2183 12.0 44.1 13.3
TB
Not presumptive case 54 496 5073 36 151 3192 8.8 8265 15.2 38.6 16.9
On treatment 161 92 51 12 23.5 104 64.6 11.5 67.1
Presumptive case 668 144 466 189 40.6 333 49.9 56.8 52.7
Pregnant
Not pregnant 50 788 4952 33 782 3129 9.3 8081 15.9 38.7 17.6
Pregnant 4260 331 2672 240 9.0 571 13.4 42.0 15.2
Missing 277 26 214 24 11.2 50 18.1 48.0
STI
Not symptomatic 54 220 5145 35 843 3189 8.9 8334 15.4 38.3 17.1
Symptomatic 1000 161 756 204 27.0 365 36.5 55.9 38.2
Missing 105 3 69 0 0.0 3 2.9 0.0
CHiPs, Community HIV Providers; HIVþ, HIV-positive; STI, sexually transmitted infections; TB, tuberculosis.27.0% in women) as well as TB patients (27.6% in men
and 23.5% in women).
Overall, the number of individuals known to have HIV
increased by 66% as a result of the CHiPs intervention
(7732 before versus 12 840 after). The relative benefit for
the intervention varied between communities (varying
from 29.6% in community 1 to 50.2% in community 2
in men and from 30.4 to 38.2% in women) and age
groups [highest attribution was in the young age groups:
20–24 years (73.4%) in men and the age groups 18–19
(70.5%) in women].
HIV-prevalence
Overall HIV-prevalence was higher in women than men
(17.5% compared with 10.3%). Expectedly, the highest
prevalence was found in those on TB treatment, with TB
or STI symptoms, similar to the trend in the newly
diagnosed HIV positives (Tables 2 and 3). Overall,
prevalence estimates were higher in women for most risk-
factor categories including age. Copyright © 2017 Wolters KluweKnowledge of HIV status before and after the
PopART intervention
Approximately, 41.1% of consenting men knew their
HIV status before the intervention and this increased to
88.2% after the intervention. Similarly, approximately
54.6% of consenting women knew their HIV status
before the intervention, and this increased to 91.6% after
the intervention (Fig. 2).
The highest impact of the intervention in terms of
knowing one’s HIV-status was in the youngest age groups
(18–19 years) in which knowledge of HIV status
increased from 27.3 to 91.3% in men and from 42.2 to
94.5% in women.
Additional value of repeated visits
Among those who accepted the offer of HCT,
approximately 73.6% of women tested on the first visit
to the household compared with only 52.7% in men.
Among those who tested at any time during round one,
26.4% (9664/36 668) of women and 47.3% (14 282/r Health, Inc. All rights reserved.
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Fig. 2. Knowledge of status before and after the intervention by sex and age.30 2260) of men tested after the date their household was
first visited.
Among those who accepted HCT at any time, the
proportion of men who tested at a repeat visit, rather than
the first visit to their household, was highest in those aged
40–49 years (52.7%) in men and those aged 18–19 years
(33.7%) in women. The interquartile range across age
groups was 44.7–52.7% for men and 22.0–33.7% for
women (data not shown).Discussion
The current study provides important insight into the
feasibility of delivering the first ‘90’ of the UNAIDS 90–
90–90 targets under ‘real life’ conditions in SSA. To our
knowledge, there are relatively few community-based
population interventions exploring this to the magnitude
of this study [14–16]. In contrast to other ongoing UTT
trials, which were undertaken in smaller rural commu-
nities, we show that within a high HIV prevalence
generalized epidemic in urban and periurban resource-
limited settings, overall acceptance of HIV-testing
through offering a door-to-door-based combination
HIV prevention package was 72.2%. After one complete
round of the PopART intervention, the percentage of
participants who knew their HIV status increased from
50 to90%, among those consenting, with the greatest
impact being in the younger age groups.
The current study demonstrates that large-scale HB-
HCT is well accepted, feasible, and effective in reaching
the majority of resident population of a community
consistent with findings from prior studies and other
ongoing large-scale trials [13,16,17]. In addition, we
demonstrate the additional value of revisits to increase
coverage for HB-HCT to contact those who are absent or Copyright © 2017 Wolters Kluwer Hhad previously declined testing. We show that for both
men and women, repeat visits are important across the age
range, and particularly necessary to reach men.
HCT uptake was associated with younger age, sex, and
community, being symptomatic for TB and STI and
longer time since previous HIV testing, consistent with
findings from other studies [18–21]. Contextual hetero-
geneity has been shown to influence HCTuptake due to
factors such as physical features, social organization,
networks, and narratives [22]. Although the study
communities were selected on the basis of common
characteristics, they still have significant differences such
as presence of other HIV testing options or stakeholders,
scale of informal/formal populations, mobility patterns,
quality of clinic services, and management of CHiPs’
teams. In communities 2 and 4, proportionally more
adults took up the opportunity to be tested because of
availability of several different HIV stakeholders levels and
a high number of local HCT options [22]. In contrast,
historically community 1 had fewer HIVefforts and has a
stronger middle-income presence with more formal
employment options which decreases the possibility of
finding people at home [22].
HCTuptakewas similar by sex, but it was much harder for
CHiPs to contact men at home compared with women
due to social-economic reasons such as beer-drinking and
informal employment which takes them away from home
[22]. Various initiatives such as community-based male
health campaigns, weekend appointments, and HIV
testing campaigns were tested to contact more men.
These have been shown to increase HIV uptake [23,24].
Participants aged 50 years and older were more likely to
decline HCT compared with the youngest age group.
This is consistent with other studies that have found that
such older age groups were associated with ‘never had anealth, Inc. All rights reserved.
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site. In addition, we demonstrate that there is a relatively
lower yield of newHIV-positive diagnoses amongst those
50 years and above and therefore they may not be a
priority screening group. Uptake of HCT was high
among women due to prior increased testing access at
antenatal clinics before the CHiPs visit. Contrary, studies
have shown that HCTuptake is lower in men regardless of
the type of HCT offered [6,20,21].
Participants reporting symptoms of STI and/or TB had
higher HCT uptake compared with asymptomatic ones
probably due to perception of risk. According to the
2013–2014 DHS in Zambia, respondents with an STI or
STI symptoms in the previous 12 months were more
likely to be HIV-positive than those without (25 versus
14%) [2]. Similarly, in the Zimbabwe DHS men had
higher odds of HCT uptake if reporting an STI in the
previous 12 months (aOR 1.86; 95% CI: 1.26–2.74),
whereas for women, visiting ANC [aOR 5.48; 95% CI
(4.08–7.36)] was the most significant predictor of being
tested [5].
The current study is being implemented under ‘real life’
conditions using a very large cadre of local community
health workers. The survey design and sampling enables
us to draw conclusion which should be broadly
generalizable to other periurban/urban settings. How-
ever, the intervention is resource intensive, and it may be
more feasible to deliver streamlined and targeted
approaches.
Our analysis has distinguished the contributions of age,
community, and previous testing and actually found
relatively little confounding although these three factors
are associated with each other and with HCTuptake. The
factors explored in this article are not exhaustive as other
important factors have been reported elsewhere [20,25].
We did not ask about reasons for declining HCT in the
first round of the intervention but have subsequently
done so in the second round. In a nested case–control
study to examine factors associated with acceptance of
HB-HCT delivered by CHiPs in the HPTN 071 trial,
data from 642 participants showed no differences between
cases and controls by demographic or behavioural
characteristics (unpublished work).
We suggest that a UTT approach, delivered with the
support of HB-HCT, should help in delivering the
UNAIDS 90–90–90 targets designed to bring the global
HIV epidemic under control.
Conclusion
At a time when UTT is thought to be an effective strategy
to eliminate HIV transmission, additional and innovative
strategies will be required to reach ‘universal HIV testing’.
By offering a HB-HCT programme, the uptake of testing
can be increased to 72.2%, but challenges still remain in Copyright © 2017 Wolters Kluwefinding men and a one-off intervention is unlikely to be
successful but will require repeated visits and multiple
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